The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
- 8 July 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 5 (9) , 531-542
- https://doi.org/10.1038/ncponc1179
Abstract
Nature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.Keywords
This publication has 90 references indexed in Scilit:
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerProceedings of the National Academy of Sciences, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997